Prompt: Summarize the business model from the following text. Answer with a continuous text and with fivehundredtwelve tokens at max. Set your focus on sources of revenue , the intended customer base , products , distribution channels  and details of financing. Use only information from the following the text:


PART I | 1 
---------+--------------------------------------------------------------------------------------
ITEM 1. | BUSINESS | 1 
 | FORWARD-LOOKING STATEMENTS | 1 
 | OVERVIEW | 2 
 | THERMODOX® (DOXORUBICIN ENCAPSULATED IN HEAT-ACTIVATED LIPOSOME) | 8 
 | THERMODOX® IN RELATION TO PRIMARY LIVER CANCER | 8 
 | Liver Cancer Overview | 8 
 | Celsion’s Approach | 9 
 | Phase I Clinical Trial – Primary Liver Cancer | 9 
 | 701 Patient Phase III Global Clinical Trial – Primary Liver Cancer (The HEAT Study) | 9 
 | 550 Patient Phase III Global Clinical Trial – Primary Liver Cancer (The OPTIMA Study) | 9 
 | GEN-1 (IL-12 DNA PLASMID VECTOR ENCASED IN A NANOPARTICLE DELIVERY SYSTEM) | 11
 | Ovarian Cancer Overview | 11
 | Celsion’s Approach | 12
 | GEN-1 OVATION Study | 12
 | THERAPLAS TECHNOLOGY PLATFORM | 14
 | BUSINESS STRATEGY AND DEVELOPMENT PLAN | 14
 | RESEARCH AND DEVELOPMENT EXPENDITURES | 15
 | GOVERNMENT REGULATION | 15
 | Regulation in the United States | 15
 | Research and Development | 15
 | Orphan Drug Designation | 18
 | Hatch-Waxman Exclusivity | 18
 | Post-Approval Requirements | 19
 | Regulation outside of the U.S | 19
 | MANUFACTURING AND SUPPLY | 20
 | SALES AND MARKETING | 21
 | PRODUCT LIABILITY AND INSURANCE | 21
 | COMPETITION | 21
 | ThermoDox® | 21
 | GEN-1 | 21
 | INTELLECTUAL PROPERTY | 21
 | Licenses | 21
 | Patents and Proprietary Rights | 22
 | EMPLOYEES | 22
 | COMPANY INFORMATION | 23
 | AVAILABLE INFORMATION | 23
 | RECENT EVENTS | 23
ITEM 1A. | RISK FACTORS | 23
ITEM 1B. | UNRESOLVED STAFF COMMENTS | 38
ITEM 2. | PROPERTIES | 38
ITEM 3. | LEGAL PROCEEDINGS | 38
ITEM 4. | MINE SAFETY DISCLOSURES | 38

 
 i



CELSION CORPORATION
 FORM 10-K
 TABLE OF CONTENTS (continued)
 
